C12N2830/006

REGULATABLE EXPRESSION SYSTEMS

Provided herein are regulatable expression systems and methods of using said regulatable expression systems to express proteins of interest. The regulatable expression systems comprise a unidirectional regulatable promoter operably linked to a single transcription unit encoding a protein of interest, a ribosome skip, and a transactivator protein.

Recombinant adenoviral vector expressing Zika antigen with improved productivity

Provided herein are adenoviral vectors comprising nucleotide sequences encoding a Zika virus M and Env antigen, wherein the nucleotide sequence encoding the Zika virus M and Env antigen is operably linked to a cytomegalovirus (CMV) promoter comprising at least one tetracycline operator (TetO) motif. Also provided herein are pharmaceutical compositions comprising the adenoviral vectors, methods of producing the adenoviral vectors, methods of preventing Zika virus or the progression of Zika virus in a subject in need thereof, and kits comprising the adenoviral vectors and host cells.

NEW GENERATION REGULATABLE FUSOGENIC ONCOLYTIC HERPES SIMPLEX VIRUS TYPE 1 VIRUS AND METHODS OF USE
20230026342 · 2023-01-26 · ·

Malignant tumors that are resistant to conventional therapies represent significant therapeutic challenges. An embodiment of the present invention provides a new generation regulatable fusogenic oncolytic herpes simplex virus-1 that is more effective at selective killing target cells, such as tumor cells. In various embodiments presented herein, the oncolytic virus described herein is suitable for treatment of solid tumors, as well as other cancers.

CODON OPTIMIZED NEW GENERATION REGULATABLE FUSOGENIC ONCOLYTIC HERPES SIMPLEX VIRUS TYPE 1 VIRUS AND METHODS OF USE
20220409684 · 2022-12-29 · ·

Malignant tumors that are resistant to conventional therapies represent significant therapeutic challenges. An embodiment of the present invention provides a codon optimized new generation regulatable fusogenic oncolytic herpes simplex virus-1 that is more effective at selective killing target cells, such as tumor cells. In various embodiments presented herein, the oncolytic virus described herein is suitable for treatment of solid tumors, as well as other cancers.

METHODS FOR REPROGRAMMING SOMATIC CELLS
20220403344 · 2022-12-22 ·

The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.

DUAL VIRUSES AND DUAL ONCOLYTIC VIRUSES AND METHODS OF TREATMENT

The present disclosure provides dual viruses capable of producing a primary virus and a secondary virus, and dual oncolytic viruses capable of producing a primary oncolytic virus and a secondary oncolytic virus.

Modified adenoviruses

Compositions include modified adenoviruses. Nucleotides, cells, and methods associated with the compositions, including their use as vaccines. Viral vectors using a TET promoter system and methods of producing viruses having the same.

Methods for reprogramming somatic cells

The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.

SYSTEMS AND METHODS FOR BATCH CULTIVATION OF NON-TRANSGENIC HETEROGAMETES
20220330533 · 2022-10-20 ·

A system for batch production of the heterogametic sex of a biological species generally includes a first strain of a biological species genetically engineered to include a conditional Y-linked (or Z-linked) genetic lethal circuit and a second strain of the biological species genetically engineered to include a conditional X-linked (or W-linked) genetic lethal circuit.

Eukaryotic cell line
11643666 · 2023-05-09 · ·

The present invention relates to a cell line, use of the cell line and a method for producing infectious viral particles using said cell line.